| Advair Diskus Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| Advair Diskus 500 mcg-50 mcg | powder | inhalation | 1.0 inhalation | OTC |
| Advair Diskus 500 mcg-50 mcg | powder | inhalation | 1.0 inhalation | OTC |
| Advair Diskus 250 mcg-50 mcg | powder | inhalation | 1.0 inhalation | OTC |
| Advair Diskus 100 mcg-50 mcg | powder | inhalation | 1.0 inhalation | OTC |
Posted by onlechat1 5 days ago
I am suddenly experiencing double vision and wonder if Advair is at fault. Would be interested to hear of such a side effect.
K
Posted by desoljo 12 days ago
I have had EXTREME hair loss and I did not know what from. I never thought it was my advair. I checked all of my other medica...
Posted by billybgame 17 days ago
I'm now 43, and I've had bad allergy symptoms since about age 17. Perennial symptoms and nearly daily headaches and facial p...
Glaxo's Advair Lowers Death Risk in Smoker's Cough (Update1) - Bloomberg
28 (Bloomberg) -- GlaxoSmithKline Plc's Advair Diskus inhaler cut the risk of death in people with a lung condition caused by smoking more than Boehringer ...
Fri Dec 28 03:54:26 -0500 2007
Glaxo's Advair Lowers Death Risk in Smoker's Cough (Update2) - Bloomberg
all 60 news articles
Fri Dec 28 06:07:57 -0500 2007
Pearl Therapeutics, Inc. Expands Its Senior Management Team With ... - SunHerald.com
Dr. Reisner played a diverse and integral role in the development of several key products including Advair(R) Diskus(R) and Serevent(R) Diskus(R) for COPD, ...
Thu Dec 20 08:44:59 -0500 2007
fluticasone propionate - The propionate salt form of fluticasone, a synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. Binding and activation of the glucocorticoid receptor results in the activation of lipocortin that in turn inhibits cytosolic phospholipase A2, which triggers cascade of reactions involved in synthesis of inflammatory mediators, such as prostaglandins and leukotrienes. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.
salmeterol xinafoate